High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers

• US 5,888,778 A
• Filed: 06/16/1997
• Issued: 03/30/1999
• Est. Priority Date: 06/16/1997
• Status: Expired due to Term

• Current Assignee: Esoterix Genetic Laboratories LLC (Laboratory Corporation Of America Holdings)
• Original Assignee: Exact Laboratories, Inc.
• Inventors: Shuber, Anthony P.
• Primary Examiner(s): Sisson, Bradley L.
• Application Number:
  US08/877,333
• Time in Patent Office: 652 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 435/183, 536/23.1, 536/24.3, 536/24.31, 536/24.33, 536/25.3, 935/8, 935/26, 935/77, 436/94
• US Class Current: 435/91.1
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6869 Methods for sequencing
• CPC Class Codes: C12Q 2525/107 incorporating a peptide nucleic acid
• CPC Class Codes: C12Q 2525/204 specific length of the oligonucleotides
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides

Abstract

Methods are provided for high-throughput screening for the presence of genetic alterations and disease-causing microorganisms in a biological sample. These methods are particularly useful for identifying individuals with gene mutations indicative of early colorectal cancer.

Claims

1. A method for screening genomic nucleic acid samples to identify a nucleic acid mutation comprising the steps of:

(i) isolating a plurality of genomic nucleic acids;

(ii) exposing said nucleic acids to one or more segmented primers, each comprising a first primer having a length between 5 and 8 nucleotides, and a second primer having a length between 15 and 100 nucleotides and a 3'"'"' non-extendible nucleic acid, wherein said first and second primers hybridize to regions of a target nucleic acid that are separated by no more than one nucleotide on said target and wherein said second primer binds upstream of said first primer;

(iii) conducting a template-based nucleic acid extension reaction, thereby to add a single terminal nucleotide to one or more of said first probes;

(iv) isolating extended first probes; and

(v) determining the sequence of said extended first probes;

thereby to detect the presence or absence of a genetic alteration.

2. The method of claim 1, wherein said mutation is selected from the group consisting of insertions, deletions, and substitutions.

3. The method of claim 1, wherein said nucleic acid samples are human nucleic acids.

4. The method of claim 1, wherein said mutation is causative of a disease selected from the group consisting of cystic fibrosis, β

-thalassemia, Tay-Sachs disease, sickle cell anemia, and Gaucher'"'"'s disease.

5. The method of claim 1, wherein at least one of said target nucleic acids is amplified prior to said exposing step.

6. The method of claim 1, wherein said second probe is a peptide nucleic acid.

7. The method of claim 1, wherein said single terminal nucleotide is a haptenated non-wild-type nucleotide.

8. The method of claim 7, wherein said isolating step comprises:

(i) dissociating extended first probes from target nucleic acids;

(ii) immobilizing said extended first probes on a hapten-specific solid-phase support; and

(iii) washing said solid-phase support to remove unbound first and second probes and terminal nucleotides.

9. The method of claim 1, wherein said determining step comprises chemical sequencing.

10. A method for screening genomic nucleic acid samples to identify a mutation comprising the steps of:

(i) immobilizing a plurality of genomic nucleic acids on a solid phase support;

(ii) exposing said immobilized nucleic acids to one or more segmented primers, each comprising a first primer having a length between 5 and 8 nucleotides and a second primer having a length between 15 and 100 nucleotides and a 3'"'"' non-extendible nucleic acid, wherein said first and second primers hybridize to regions of a target nucleic acid that are separated by no more than one nucleotide on said target and wherein said second primer binds upstream of said first primer;

(iii) conducting a template-based nucleic acid extension reaction, thereby to add a single terminal nucleotide to one or more of said first probes;

(iv) isolating extended first probes; and

(v) determining the sequence of said extended first probes;

thereby to detect the presence or absence of a genetic alteration.

11. The method of claim 10, wherein said solid-phase support is selected from the group consisting of nitrocellulose filter, nylon filter, magnetic beads, glass beads, and plastic.

12. The method of claim 10, wherein said first probe and said second probe form an exactly contiguous primer.

13. A method for high-throughput screening of genomic nucleic acid samples to identify one or more genetic alterations in one or more target nucleic acid sequences present in said samples, comprising the steps of:

(i) isolating a plurality of genomic nucleic acids;

(ii) exposing said nucleic acids to an excess amount of one or more segmented primers, each comprising a first primer having a length between 5 and 8 nucleotides, and a second primer having a length between 15 and 100 nucleotides and a 3'"'"' non-extendible nucleic acid, wherein said first and second primers hybridize to regions of a target nucleic acid that are separated by no more than one nucleotide on said target and wherein said second primer binds upstream of said first primer;

(iii) conducting a template-based nucleic acid extension reaction in the presence of a heat-stable polymerase and an excess amount of labeled non-wild-type nucleotides, thereby to add a single labeled terminal nucleotide to one or more of said first probes;

(iv) heating the extension reaction mixture of step (iii), thereby to dissociate said first probes and said second probes from said target nucleic acids;

(v) cooling the extension reaction mixture of step (iv), thereby to expose said target nucleic acids to said excess amount of segmented primers;

(vi) repeating step (iii);

(vii) isolating extended labeled first probes; and

(viii) determining the sequence of said extended labeled first probes;

thereby to detect the presence or absence of a genetic alteration.

14. The method according to claim 13, wherein step (iv) to step (vi) are repeated 10 to 50 times.

15. The method according to claim 13, wherein step (iv) to step (vi) are repeated 30 times.